Novartis headquarters

Novartis headquarters

File photo taken Jan. 27, 2024, shows the headquarters of Swiss pharmaceutical company Novartis AG in Basel.

Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, holds talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura (R) at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein, division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks with reporters after holding talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis Pharma

Novartis Pharma

TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.

Novartis Japan unit faces business suspension order

Novartis Japan unit faces business suspension order

Photo taken June 12, 2014, shows the building in Tokyo's Minato Ward housing a Japanese unit of Swiss pharmaceutical maker Novartis AG. The health ministry has decided to order a business suspension of around 15 days for the Tokyo-based company for not reporting serious side effects of its drugs, sources close to the matter said on Feb. 2, 2015. (Kyodo) ==Kyodo

Novartis Pharma unveils preventive measures against misconduct

Novartis Pharma unveils preventive measures against misconduct

Dirk Kosche, president of Novartis Pharma K.K., the Japanese unit of Swiss pharmaceutical maker Novartis AG, bows in apology during a press conference in Tokyo on June 9, 2015. Kosche unveiled measures to prevent the reoccurrence of company misconduct involving not reporting serious side effects of its drugs. (Kyodo) ==Kyodo